title: Differences in mucosal appearances and in relapse rates in duodenal ulceration treated with sucralfate or cimetidine.
abstract: A total of 46 patients with duodenal ulcer were randomly assigned, without the knowledge of the investigators, to treatment with cimetidine 200 mg three times daily and 400 mg at night or sucralfate 1 g four times daily followed by one year of maintenance treatment with cimetidine 400 mg at night or sucralfate 1 g twice daily, respectively, in those patients with healed ulcers. The endoscopic healing rates and relapse rates during the maintenance period were similar, four relapses occurring in each group. All four relapses in the sucralfate group occurred at 12 months and only two were symptomatic. All the cimetidine relapses were symptomatic, two occurring at six months, one at nine months, and one at 12 months. Following the one year maintenance period, 13 cimetidine patients and 11 sucralfate patients were followed up for 36 months. During the first two years, nine of 13 (69 percent) cimetidine-treated and two of 11 (18 percent) sucralfate-treated patients had relapses. During the third year, three more sucralfate-treated patients and one more cimetidine-treated patient had relapses, making a total of 10 of 13 (77 percent) and five of 11 (45 percent) in the cimetidine and sucralfate groups, respectively. Duodenal biopsy specimens obtained before and after healing and after one year of maintenance were examined by light and electron microscopy. The sucralfate group showed greater improvement after one year of maintenance therapy than did the cimetidine group, although the appearances in either group were not predictive of subsequent relapse. The results show that relapses are less frequent and occur later after sucralfate therapy and also that the morphologic appearances are more normal after treatment with sucralfate than after treatment with cimetidine.
authors.affiliation: Department of Surgery, Basingstoke District Hospital, United Kingdom.
authors.forename: F I
authors.initials: FI
authors.lastname: Tovey
authors.forename: E M
authors.initials: EM
authors.lastname: Husband
authors.forename: Y C
authors.initials: YC
authors.lastname: Yiu
authors.forename: L
authors.initials: L
authors.lastname: Baker
authors.forename: G
authors.initials: G
authors.lastname: McPhail
authors.forename: A P
authors.initials: AP
authors.lastname: Jayaraj
authors.forename: M R
authors.initials: MR
authors.lastname: Lewin
authors.forename: C G
authors.initials: CG
authors.lastname: Clark
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002927:Cimetidine / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000473:pathology*; D004386:Duodenum / Q000473:pathology; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012008:Recurrence; D013392:Sucralfate / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D013392:Sucralfate; D002927:Cimetidine